|Bid||0.1350 x 1582700|
|Ask||0.1450 x 3535900|
|Day's range||0.1350 - 0.1450|
|52-week range||0.1050 - 0.3850|
|Beta (5Y monthly)||0.87|
|PE ratio (TTM)||N/A|
|Earnings date||25 July 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
The underwhelming share price performance of Cynata Therapeutics Limited ( ASX:CYP ) in the past three years would have...